Wed. 27 Mar 2024, 2:40am ET
Benzinga
News
Once issued, this patent is expected to expire no earlier than October 2039. The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.